ClinicalTrials.gg
TerminatedNCT03015961Updated Oct 13, 2021Results posted

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

A Phase 4 interventional study of EXPAREL and bupivacaine HCl and Bupivacaine HCl in Postoperative Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment

Why this study was terminated
Slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.

Enrollment
72nd of 93
38 · median 80
Started
2017
with 7 others
Phase 4
52 of 93
5 open now
Registered
27th of 93
by date
Lead sponsor
11 of 93
Pacira Pharmaceuticals, Inc

Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 72nd largest by enrollment, is one of 8 that started in 2017, is one of 52 in phase 4, and was the 27th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Liposomal Bupivacaine

Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Primary Objective: The primary objective of this study is to compare postsurgical pain control following local infiltration analgesia (LIA) with EXPAREL admixed with bupivacaine HCl versus LIA with bupivacaine HCl in adult subjects undergoing open lumbar posterior spinal fusion surgery.

Secondary Objectives: The secondary objectives of this study are to compare additional efficacy, safety, and health economic outcomes following LIA with EXPAREL admixed with bupivacaine HCl versus LIA with bupivacaine HCl in adult subjects undergoing open lumbar posterior spinal fusion surgery.

Read the detailed description

This is a Phase 4, multicenter, randomized, double-blind, controlled study in 38 adult subjects undergoing primary, 1-2 level, open lumbar spinal fusion surgery under general anesthesia.

Subjects will be screened within 30 days prior to study drug administration and at least one day prior to surgery. During the screening visit, subjects will be assessed for past or present neurologic, cardiac, and general medical conditions that in the opinion of the Investigator would preclude them from study participation. After the informed consent form (ICF) is signed, a medical history, surgical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, select clinical laboratory evaluations, urine drug screen, alcohol breath test, and urine pregnancy test for women of childbearing potential will be conducted. Study drug, approximately 1-2 mL every 1.0-1.5 cm, will be administered using 20- or 22-gauge needles prior to wound closure.

Administration Instructions/Procedures

Study drug should be injected in the prescribed locations based on the areas of highest nerve density. Study drug will be administered using syringes with 20- or 22-gauge needles prior to wound closure. The Investigator must document the size of the incision. Each infiltration site should be spaced 1.0-1.5 cm apart and should deliver approximately 1-2 mL into both deep and superficial areas (para-spinous fascia, muscle, and subcutaneous layers). Total volume administered will be depended on the number of levels of dissection, as described below. Following infiltration, the tissue should visibly expand with minimal leakage.

Total Volume of Expansion

The Investigator must document the total volume used for each surgery.

  1. Level Procedures Group 1: EXPAREL 266 mg in 20 mL + bupivacaine HCl 0.5% in 20 mL + 20 mL normal saline = total volume of 60 mL Group 2: Bupivacaine HCl 0.5% in 20 mL + 40 mL normal saline = total volume of 60 mL
  2. Level Procedures Group 1: EXPAREL 266 mg in 20 mL + bupivacaine HCl 0.5% in 20 mL + 50 mL normal saline = total volume of 90 mL Group 2: Bupivacaine HCl 0.5% in 20 mL + 70 mL normal saline = total volume of 90 mL

Drains may be used at the surgeon's discretion. In addition to LIA, all study participants will receive a standardized approach for managing postsurgical pain that includes a scheduled multimodal pain regimen including adjunctive analgesics, non-steroidal anti-inflammatory drugs (NSAIDs). Rescue analgesics will be available as needed.

Postsurgical clinical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS) (see Appendix 1); overall benefit of analgesia score (OBAS) questionnaire (see Appendix 2); total postsurgical opioid consumption; predefined opioid-related AEs; and nurse's satisfaction with overall analgesia (see Appendix 3).

Adverse events will be recorded from the time the ICF is signed through Day 30. If a cardiac AE (e.g., chest pain [angina, myocardial infarction], abnormal/irregular heart rate [bradycardia, tachycardia, extrasystoles], or shortness of breath), neurological AE (e.g., altered mental status/altered sensorium, dizziness, dysarthria, hyperesthesia, metallic taste, peroral numbness, seizure, tinnitus, tremors, visual disturbance, muscular twitching or rigidity beyond 72 hours postdose, or tingling/paresthesia beyond 72 hours postdose), or serious AE (SAE) occurs during the study a 12-lead ECG, vital signs, and any appropriate clinical laboratory tests should be conducted.

Postsurgical health economic outcome assessments will include hospital length of stay (LOS), use of skilled nursing facility, hospital readmissions, and use of other health services following discharge (phone calls related to postsurgical pain, unscheduled visits related to postsurgical pain, and visits to emergency department) through Day 30.

A follow-up visit will be scheduled for all subjects on postsurgical Day 14. A follow-up phone call will be made on Day 30 to all subjects who received study drug to assess for adverse events (AEs).

Number of Subjects (Planned):

Approximately 194 subjects are planned for enrollment in this study in order to have at least 184 evaluable subjects.

03

Conditions studied

  • Postoperative Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, at least 18 years of age at screening.
  2. Primary surgical indication is lumbar pain, radiculopathy, disc degeneration, disc herniation, foraminal stenosis, or 1-2 level spondylolisthesis or deformity.
  3. Scheduled to undergo primary, 1-2 level, open lumbar spinal fusion surgery under general anesthesia.
  4. (ASA) physical status 1, 2, or 3.
  5. Female subjects must be surgically sterile; or at least 2 years ; or have a monogamous partner who is surgically sterile; or practicing double-barrier ; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, or transdermal, contraceptive approved by the FDA for greater than 2 months prior to screening. All women of (ie, premenopausal without permanent sterilization) must commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study.
  6. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  2. Serious spinal conditions (to include cauda equina syndrome, infection, tumor, fracture, or severe osteoporosis [ie, if taking Bisphosphonate or TNF-α blockers]).
  3. Planned anterior or lateral incisions
  4. Previous spinal surgery at the same level other than microdiscectomy or hemilaminectomy (eg, bi-lateral laminectomy, fusion).
  5. Planned concurrent surgical procedure.
  6. Identification of a dural tear during surgery will be an intra-operative exclusion unless it is well repaired (no evidence of cerebrospinal fluid [CSF] leak with Valsalva and no plan to restrict activity post-operatively). Any injury to the nerve root occurring during surgery will also be considered an intra-operative exclusion.
  7. Concurrent painful physical condition that may require analgesic treatment (such as an NSAID or opioid) in the postsurgical period for pain that is not strictly related to the spinal surgery and which may confound the postsurgical assessments.
  8. Comorbidity impacting current physical function or Investigator opinion that it may impact postsurgical rehabilitation.
  9. Allergy, , or to any of the study medications (ie, bupivacaine, oxycodone, morphine, hydromorphone, gabapentin, acetaminophen, or cyclobenzaprine) for which an alternative medication is not provided in the protocol.
  10. Use of any of the following medications within the times specified before surgery: long-acting opioid medication (eg, morphine including MS Contin®, hydromorphone [Dilaudid®], oxycodone [Oxycontin®], methadone) daily for more than 3 months duration or within 3 days of surgery. Patients receiving short-acting opioids or NSAIDs should be at a steady or plateau dose. Such patients should require or receive no more than 40 mg morphine (oral) equivalents (eg, approximately 5 mg oxycodone) within 24 hours of surgery.
  11. Initiation of treatment with any of the following medications within 1 month of study drug administration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to study drug administration.
  12. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
  13. Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration.
  14. History of coronary or vascular stent placed within the past 3 months (may be extended to 1 year if medically indicated per physician discretion).
  15. Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
  16. Severely impaired renal (eg, serum ≤ 30) or hepatic function (eg, serum [AST] level >3 times the [ULN] or serum alanine aminotransferase [ALT] level >3 x ULN).
  17. Any neurologic or psychiatric disorder that might impact postsurgical pain or interfere with study assessments.
  18. in the last 2 years, per physician discretion.
  19. History of misuse, abuse, or dependence on opioid analgesics, other prescription drugs, illicit drugs, or alcohol as defined in . Dependence or chronic opioid use will be defined as use of more than 30 morphine equivalents per day during the prior 90 days.
  20. Failure to pass the alcohol breath test or urine drug screen positive for illicit drugs.
  21. Body weight \<50 kg (110 pounds) or a >44 kg/m2.
  22. Subjects receiving Worker's compensation for a disability or who are involved in litigation.
  23. Previous participation in an EXPAREL study.
  24. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    EXPAREL admixed with bupivacaine HCl

    EXPAREL 266 mg + bupivacaine HCl

    Drug: EXPAREL and bupivacaine HCl

  • Placebo comparator
    Bupivacaine HCl

    Bupivacaine HCl

    Drug: Bupivacaine HCl

Interventions

  • DrugEXPAREL and bupivacaine HCl

    Drug page: Liposomal Bupivacaine

    Drug: EXPAREL EXPAREL and bupivacaine HCl Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5% Other Name: bupivacaine HCl

  • DrugBupivacaine HCl

    Drug: Bupivacaine Single dose of bupivacaine HCl 0.5% Other Name: bupivacaine HCl

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 0 to 72 Hours

    AUC of VAS pain intensity scores from 0 to 72 hours postsurgery. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now." AUC curve is derived using the trapezoidal rule (see formula below) on the pain scores. AUC start with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 72 hours post-surgery. (Where pi is the VAS pain score at time i and ti is the time, in hours, from end of surgery. Note t1 is pain score collected after surgery.)

    Time frame: 0-72 hours

Other outcomes

  1. Percentage of Opioid-Free Patients

    Percentage of opioid-free patients through 24, 48 and 72 hours post-surgery

    Time frame: 0-24, 0-48, 0-72 hours

  2. Area Under the Curve (AUC) of the Visual Analog Scale (VAS) Pain Intensity Scores From 24-48 and 48-72 Hours Postsurgery

    AUC of the VAS pain intensity scores from 24-48 and 48-72 hours postsurgery. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now." AUC from 24-48 hours start with the pain assessment obtained at 24 hours post-surgery and use all subsequent pain assessments up to 48 hours post-surgery. AUC from 48-72 hours start with the pain assessment obtained at 48 hours post-surgery and use all subsequent pain assessments up to 72 hours post-surgery. (Where pi is the VAS pain score at time i and ti is the time, in hours, from end of surgery.)

    Time frame: 24-48 hours, 48-72 hours

  3. Total Opioid Consumption Through 48 Hours Postsurgery

    Total Opioid Consumption Through 48 Hours Postsurgery

    Time frame: 0-48 hours

07

Results

Posted Oct 13, 2021
Limitations and caveats
This study was terminated early due to low enrollment; small sample sizes make data interpretation difficult.

Participant flow

Participants were recruited between February 21, 2017 and October 30, 2017 at 15 sites in the United States. The study was terminated due to low enrollment.

Participant flow — Overall Study
MilestoneEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
Started1820
Completed1818
Not completed02

Outcome measures

PrimaryArea Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 0 to 72 Hours

AUC of VAS pain intensity scores from 0 to 72 hours postsurgery. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now." AUC curve is derived using the trapezoidal rule (see formula below) on the pain scores. AUC start with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 72 hours post-surgery. (Where pi is the VAS pain score at time i and ti is the time, in hours, from end of surgery. Note t1 is pain score collected after surgery.)

Time frame:
0-72 hours
Reported as:
Mean · score on a scale*hours
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 0 to 72 Hours
score on a scale*hoursEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 0 to 72 Hours342.8 (1 to 624)369.0 (96 to 718)
Other pre-specifiedPercentage of Opioid-Free Patients

Percentage of opioid-free patients through 24, 48 and 72 hours post-surgery

Time frame:
0-24, 0-48, 0-72 hours
Reported as:
Number · percentage of opioid-free patients
Percentage of Opioid-Free Patients
percentage of opioid-free patientsEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
0-24 hours11.1111.11
0-48 hours11.115.56
0-72 hours11.115.56
Other pre-specifiedArea Under the Curve (AUC) of the Visual Analog Scale (VAS) Pain Intensity Scores From 24-48 and 48-72 Hours Postsurgery

AUC of the VAS pain intensity scores from 24-48 and 48-72 hours postsurgery. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now." AUC from 24-48 hours start with the pain assessment obtained at 24 hours post-surgery and use all subsequent pain assessments up to 48 hours post-surgery. AUC from 48-72 hours start with the pain assessment obtained at 48 hours post-surgery and use all subsequent pain assessments up to 72 hours post-surgery. (Where pi is the VAS pain score at time i and ti is the time, in hours, from end of surgery.)

Time frame:
24-48 hours, 48-72 hours
Reported as:
Mean · score on a scale*hours
Area Under the Curve (AUC) of the Visual Analog Scale (VAS) Pain Intensity Scores From 24-48 and 48-72 Hours Postsurgery
score on a scale*hoursEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
24-48 hours97.3 (0 to 185)98.1 (14 to 225)
48-72 hours86.8 (0 to 187)90.6 (8 to 162)
Other pre-specifiedTotal Opioid Consumption Through 48 Hours Postsurgery

Total Opioid Consumption Through 48 Hours Postsurgery

Time frame:
0-48 hours
Reported as:
Mean · MED, mg
Total Opioid Consumption Through 48 Hours Postsurgery
MED, mgEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
Total Opioid Consumption Through 48 Hours Postsurgery103.6 ± 101.5590.8 ± 100.58

Adverse events

Collected over From the time informed consent form is signed to Day 30. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL Admixed With Bupivacaine HCl0/18 (0%)1/18 (5.6%)11/18 (61.1%)
Bupivacaine HCl0/20 (0%)0/20 (0%)14/20 (70%)
Most frequent serious events
Most frequent serious events
EventEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/180/20
Most frequent other events
Showing 10 of 42
Most frequent other events
EventEXPAREL Admixed With Bupivacaine HClBupivacaine HCl
DizzinessNervous system disorders0/184/20
NauseaGastrointestinal disorders3/181/20
ConstipationGastrointestinal disorders3/180/20
PruritusSkin and subcutaneous tissue disorders3/180/20
Urinary tract infectionInfections and infestations3/180/20
HypotensionVascular disorders0/183/20
Incision site painInjury, poisoning and procedural complications2/182/20
AnxietyPsychiatric disorders2/180/20
Urinary retentionRenal and urinary disorders2/180/20
RadiculopathyNervous system disorders1/182/20

Baseline characteristics

All randomized subjects. The study was terminated; no efficacy outcomes were analyzed.

Age, Continuous
Age, Continuous(year)EXPAREL Admixed With Bupivacaine HClBupivacaine HClTotal
Mean57.3 ± 12.1361.6 ± 9.3359.5 ± 10.81
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL Admixed With Bupivacaine HClBupivacaine HClTotal
Female111122
Male7916
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL Admixed With Bupivacaine HClBupivacaine HClTotal
Hispanic or Latino112
Not Hispanic or Latino171936
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL Admixed With Bupivacaine HClBupivacaine HClTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White181937
More than one race000
Unknown or Not Reported000
08

Study locations

15 sites
  • OrthoArizona
    Gilbert, Arizona 85295, United States
  • St. Joseph's Hospital
    Phoenix, Arizona 85013, United States
  • UC Davis
    Sacramento, California 95817, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beaumont Health
    Troy, Michigan 48085, United States
  • Washington Univ
    Saint Louis, Missouri 63110, United States
  • Icahn School of Medicine
    New York, New York 10029, United States
  • OrthoCarolina
    Charlotte, North Carolina 28207, United States
  • Ohio State Univ
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University of Neurosurgery
    Philadelphia, Pennsylvania 19107, United States
  • Central Texas Spine Institute
    Austin, Texas 78731, United States
  • Baylor Scott & White
    Temple, Texas 76508, United States
  • Univ of Virginia
    Charlottesville, Virginia 22903, United States
  • Colonial Orthopaedics
    Colonial Heights, Virginia 23834, United States
  • West Virginia University Hospitals
    Morgantown, West Virginia 26506, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Oct 2017, 8 months.

Results were first posted in Oct 2021, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2016
First posted
Jan 10, 2017
StartActual
Feb 21, 2017
Primary completionActual
Oct 30, 2017
CompletionActual
Oct 30, 2017
Results first posted
Oct 13, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03015961
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Feb 21, 2017
Primary completion
Oct 30, 2017
Completion
Oct 30, 2017
Results posted
Oct 13, 2021
Last update
Oct 13, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion